Monitoring of minimal residual disease in acute myeloid leukemia: Methods and best applications

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue SUPPL.1, 2011, Pages

  Jorgensen, Jeffrey L ^a   Chen, Su S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Flow cytometry; Minimal residual disease; Molecular diagnostics Polymerase chain reaction

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CLINICAL ASSESSMENT; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; FLOW CYTOMETRY; HUMAN; IMMUNE DEFICIENCY; MINIMAL RESIDUAL DISEASE; MOLECULAR DIAGNOSIS; PATIENT MONITORING;

EID: 84860557379     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.03.023     Document Type: Conference Paper

References (14)

1. Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010; 22:656-63.
2. Arber DA, Brunning RD, Le Beau MM, et al. Acute myeloid leukemia with recurrent genetic abnormalities. In: Swerdlow S, Campo E, Harris N, eds. WHO Classification of Tumours: Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:110-123.
3. Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 2010; 28:3724-9.
4. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct preemptive arsenic trioxide therapy. J Clin Oncol 2009; 27:3650-8.
5. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009; 114:2220-31.
6. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European Leukemia Net study. J Clin Oncol 2009; 27:5195-201.
7. Bains A, Luthra R, Medeiros LJ, et al. FLT3 and NPM1 mutations in myelodys-plastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol 2011; 135:62-9.
8. Frankel W, Chan A, Corringham RE, et al. Detection of chimerism and early engraftment after allogeneic peripheral blood stem cell or bone marrow transplantation by short tandem repeats. Am J Hematol 1996; 52:281-7.
9. Wiedemann B, Klyuchnikov E, Kroger N, et al. Chimerism studies with quantitative realtime PCR in stem cell recipients with acute myeloid leukemia. Exp Hematol 2010; 38:1261-71.
10. Edlundh-Rose E, Egyhazi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006; 16:471-8.
11. Grossmann V, Schnittger S, Schindela S, et al. Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. J Mol Diagn 2011; 13:129-36.
12. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11:543-52.
13. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003; 123:243-52.
14. Ravandi Kashani F, Jorgensen J, Faderl S, et al. Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate-and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR). J Clin Oncol 2010;28 (15 Suppl):6527.